AMV-002

融合双质粒人乳头瘤病毒治疗性疫苗

Report date: 2026/03/30 20:02:02

Base Information

Drug NameAMV-002
Drug Alias NameHuman papillomavirus vaccine - Admedus ImmunotherapiesHPV vaccine - Admedus ImmunotherapiesAMV-002
ClassificationVaccines > Development/production technology > Nucleic acid vaccine > DNA vaccineVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsHead and Neck NeoplasmsCarcinoma, Squamous CellPapillomavirus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaIND
Originator CompaniesThe University Of QueenslandAdmedus
China Registration ClassN/A

Develop Information

Active CompaniesVgxi IncAdmedus
Inactive CompaniesN/A
Active IndicationsHead and Neck NeoplasmsCarcinoma, Squamous CellPapillomavirus Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A